Skip to content
2000
image of Astragalus Mongholicus for Idiopathic Pulmonary Fibrosis Treatment: From Molecules to Systems

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with limited treatment options. (AM), a cornerstone herb in traditional Chinese medicine (TCM), demonstrates significant therapeutic potential for IPF due to its multi-target mechanisms. This review synthesizes evidence on AM and its bioactive components; astragalus polysaccharide (APS), astragaloside IV (AS IV), and calycosin (CAL) in targeting key IPF pathological processes. These include suppression of inflammatory responses ( TLR4/NF-κB inhibition), inhibition of extracellular matrix deposition ( MMP/TIMP modulation), attenuation of oxidative stress, regulation of autophagy, and blockade of epithelial-mesenchymal transition ( lncRNA-ATB/miR-200c/ZEB1 axis). We further highlight the integration of molecular-level mechanisms with systems pharmacology to elucidate AM’s holistic actions. Clinical studies support AM-containing TCM prescriptions in improving lung function with fewer adverse effects. This synthesis underscores AM’s promise as a multi-target therapeutic agent and advocates for systematic pharmacology approaches in future IPF drug development.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240396394250911235834
2025-09-30
2025-11-01

  • From This Site

    /content/journals/cmm/10.2174/0115665240396394250911235834
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Martinez F.J. Collard H.R. Pardo A. Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Primers 2017 3 17074 29052582
    [Google Scholar]
  2. Wuyts W.A. Wijsenbeek M. Bondue B. Idiopathic pulmonary fibrosis: Best practice in monitoring and managing a relentless fibrotic disease. Respiration 2020 99 1 73 82 31830755
    [Google Scholar]
  3. George P.M. Wells A.U. Jenkins R.G. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med. 2020 8 8 807 815 32422178
    [Google Scholar]
  4. Uzel F.I. İliaz S. Karataş F. Çağlayan B. COVID-19 pneumonia and idiopathic pulmonary fibrosis: A novel combination. Turk. Thorac. J. 2020 21 6 451 453 33352102
    [Google Scholar]
  5. Libra A. Sciacca E. Muscato G. Sambataro G. Spicuzza L. Vancheri C. Highlights on future treatments of IPF: Clues and pitfalls. Int. J. Mol. Sci. 2024 25 15 8392 39125962
    [Google Scholar]
  6. Huang X. Yu W. Tian J. Identification and analysis of extracellular matrix and epithelial-mesenchymal transition-related genes in idiopathic pulmonary fibrosis by bioinformatics analysis and experimental validation. Gene 2025 956 149464 40187620
    [Google Scholar]
  7. Suzuki K. Kim J.D. Ugai K. Transcriptomic changes involved in the dedifferentiation of myofibroblasts derived from the lung of a patient with idiopathic pulmonary fibrosis. Mol. Med. Rep. 2020 22 2 1518 1526 32626975
    [Google Scholar]
  8. Sundarakrishnan A. Chen Y. Black L.D. Aldridge B.B. Kaplan D.L. Engineered cell and tissue models of pulmonary fibrosis. Adv. Drug Deliv. Rev. 2018 129 78 94 29269274
    [Google Scholar]
  9. Chen Y. Wang T. Liang F. Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice. Theranostics 2024 14 7 2794 2815 38773984
    [Google Scholar]
  10. Sathiyamoorthy G. Sehgal S. Ashton R.W. Pirfenidone and nintedanib for treatment of idiopathic pulmonary fibrosis. South. Med. J. 2017 110 6 393 398 28575896
    [Google Scholar]
  11. Jiang H. Yang L. Hou A. Botany, traditional uses, phytochemistry, analytical methods, processing, pharmacology and pharmacokinetics of Bupleuri Radix: A systematic review. Biomed. Pharmacother. 2020 131 110679 32858498
    [Google Scholar]
  12. Zhang Y. Gu L. Xia Q. Tian L. Qi J. Cao M. Radix astragali and radix angelicae sinensis in the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Front. Pharmacol. 2020 11 415 32425767
    [Google Scholar]
  13. Xin L.L. Jiang M. Zhang G. Gong J.N. Efficacy and safety of Danhong injection for idiopathic pulmonary fibrosis:Meta-analysis [Efficacy and safety of Danhong injection for idiopathic pulmonary fibrosis:Meta-analysis Zhongguo Zhongyao Zazhi 2016 41 20 3859 3865 28929667
    [Google Scholar]
  14. Zhang H.W. Wei L.Y. Zhao G. Periplaneta americana extract used in patients with systemic inflammatory response syndrome. World J. Emerg. Med. 2016 7 1 50 54 27006739
    [Google Scholar]
  15. Yao H. Wei S. Xiang Y. Kangfuxin oral liquid attenuates bleomycin-induced pulmonary fibrosis via the TGF-β1/Smad pathway. Evid. Based Complement. Alternat. Med. 2019 2019 5124026 31885648
    [Google Scholar]
  16. Huang C. Wu X. Wang S. Combination of Salvia miltiorrhiza and ligustrazine attenuates bleomycin-induced pulmonary fibrosis in rats via modulating TNF-α and TGF-β. Chin. Med. 2018 13 36 29997685
    [Google Scholar]
  17. Huang Y. Ni N. Hong Y. Lin X. Feng Y. Shen L. Progress in traditional chinese medicine for the treatment of migraine. Am. J. Chin. Med. 2020 48 8 1731 1748 33308095
    [Google Scholar]
  18. Peng L.Y. An L. Sun N.Y. Salvia miltiorrhiza restrains reactive oxygen species-associated pulmonary fibrosis via targeting nrf2-nox4 redox balance. Am. J. Chin. Med. 2019 47 5 1113 1131 31352786
    [Google Scholar]
  19. Qian W. Cai X. Qian Q. Wang D. Zhang L. Angelica sinensis polysaccharide suppresses epithelial-mesenchymal transition and pulmonary fibrosis via a DANCR/AUF-1/FOXO3 regulatory axis. Aging Dis. 2020 11 1 17 30 32010478
    [Google Scholar]
  20. Zhang J. Wu C. Gao L. Du G. Qin X. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Adv. Pharmacol. 2020 87 89 112 32089240
    [Google Scholar]
  21. Bhatt J. Ghigo A. Hirsch E. PI3K/Akt in IPF: Untangling fibrosis and charting therapies. Front. Immunol. 2025 16 1549277 40248697
    [Google Scholar]
  22. Liang Y. Yan Y. Liu N. Wang J. Fang C. Shengxian decoction improves lung function in rats with bleomycin-induced idiopathic pulmonary fibrosis through the inhibition of PANoptosis. J. Ethnopharmacol. 2024 329 118153 38604513
    [Google Scholar]
  23. Yu W.N. Sun L.F. Yang H. Inhibitory effects of astragaloside iv on bleomycin-induced pulmonary fibrosis in rats via attenuation of oxidative stress and inflammation. Inflammation 2016 39 5 1835 1841 27525425
    [Google Scholar]
  24. Hsieh H.L. Liu S.H. Chen Y.L. Huang C.Y. Wu S.J. Astragaloside IV suppresses inflammatory response via suppression of NF-κB, and MAPK signalling in human bronchial epithelial cells. Arch. Physiol. Biochem. 2022 128 3 757 766 32057253
    [Google Scholar]
  25. Xing X.Y. Qiang W.J. Bao J.L. Jinbei Oral Liquid ameliorates bleomycin-induced idiopathic pulmonary fibrosis in rats via reversion of Th1/Th2 shift. Chin. Herb. Med. 2020 12 3 273 280 36119009
    [Google Scholar]
  26. Wang X Khalil RA 2018
  27. Wu Y. Xiao W. Pei C. Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway. Int. Immunopharmacol. 2021 91 107290 33383446
    [Google Scholar]
  28. Wei Y. Qi M. Liu C. Li L. Astragalus polysaccharide attenuates bleomycin-induced pulmonary fibrosis by inhibiting TLR4/NF-κB signaling pathway and regulating gut microbiota. Eur. J. Pharmacol. 2023 944 175594 36804541
    [Google Scholar]
  29. Maksimova A.A. Shevela E.Y. Sakhno L.V. Tikhonova M.A. Ostanin A.A. Chernykh E.R. Influence of secretome of different functional phenotypes of macrophages on proliferation, differentiation, and collagen-producing activity of dermal fibroblasts in vitro. Bull. Exp. Biol. Med. 2021 171 1 49 52 34057617
    [Google Scholar]
  30. Piacenza E. Presentato A. Ambrosi E. Physical-chemical properties of biogenic selenium nanostructures produced by stenotrophomonas maltophilia SeITE02 and ochrobactrum sp. MPV1. Front. Microbiol. 2018 9 3178 30619230
    [Google Scholar]
  31. Zuo W.L. Zhao J.M. Huang J.X. Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis. Biomed. Rep. 2017 6 2 201 205 28357073
    [Google Scholar]
  32. Gao J. Feng L.J. Huang Y. Total glucosides of Danggui Buxue Tang attenuates bleomycin-induced pulmonary fibrosis via inhibition of extracellular matrix remodelling. J. Pharm. Pharmacol. 2012 64 6 811 820 22571259
    [Google Scholar]
  33. Zhi Q.M. Yang L.T. Sun H.C. Protective effect of ambroxol against paraquat-induced pulmonary fibrosis in rats. Intern. Med. 2011 50 18 1879 1887 21921364
    [Google Scholar]
  34. Zhang R. Xu L. An X. Sui X. Lin S. Astragalus polysaccharides attenuate pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition and NF-κB pathway activation. Int. J. Mol. Med. 2020 46 1 331 339 32319542
    [Google Scholar]
  35. Qian W. Cai X. Qian Q. Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition. Aging (Albany NY) 2020 12 5 4322 4336 32139663
    [Google Scholar]
  36. Yan X. Lu Q.G. Zeng L. Synergistic protection of astragalus polysaccharides and matrine against ulcerative colitis and associated lung injury in rats. World J. Gastroenterol. 2020 26 1 55 69 31933514
    [Google Scholar]
  37. Chen J. Wang G. Li L. Zhang P. Protective effect of Astragalus polysaccharide on MRC-5 cells from oxidative damage induced by hydrogen peroxide [Protective effect of Astragalus polysaccharide on MRC-5 cells from oxidative damage induced by hydrogen peroxide. Xibao Yu Fenzi Mianyixue Zazhi 2015 31 8 1062 1066 [ 26271980
    [Google Scholar]
  38. Bratkov V.M. Shkondrov A.M. Zdraveva P.K. Krasteva I.N. Flavonoids from the genus astragalus: Phytochemistry and biological activity. Pharmacogn. Rev. 2016 10 19 11 32 27041870
    [Google Scholar]
  39. Chen G. Hou Y. Li X. Pan R. Zhao D. Sepsis-induced acute lung injury in young rats is relieved by calycosin through inactivating the HMGB1/MyD88/NF-κB pathway and NLRP3 inflammasome. Int. Immunopharmacol. 2021 96 107623 33857805
    [Google Scholar]
  40. Lv X. Li K. Hu Z. Autophagy and pulmonary fibrosis. Adv. Exp. Med. Biol. 2020 1207 569 579 32671775
    [Google Scholar]
  41. Manni W Min W Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. MedComm 2022 3 4 e176. 10.1002/mco2.176
    [Google Scholar]
  42. Phan T.H.G. Paliogiannis P. Nasrallah G.K. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell. Mol. Life Sci. 2021 78 5 2031 2057 33201251
    [Google Scholar]
  43. Zheng Y. Ren W. Zhang L. Zhang Y. Liu D. Liu Y. A review of the pharmacological action of astragalus polysaccharide. Front. Pharmacol. 2020 11 349 32265719
    [Google Scholar]
  44. Li N. Feng F. Wu K. Zhang H. Zhang W. Wang W. Inhibitory effects of astragaloside IV on silica-induced pulmonary fibrosis via inactivating TGF-β1/Smad3 signaling. Biomed. Pharmacother. 2019 119 109387 31487583
    [Google Scholar]
  45. Guan Y. Zhang J. Cai X. Astragaloside IV inhibits epithelial-mesenchymal transition and pulmonary fibrosis via lncRNA-ATB/miR-200c/ZEB1 signaling pathway. Gene 2024 897 148040 38065426
    [Google Scholar]
  46. Li T. Gao X. Jia R. Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway. Cell. Mol. Biol. 2024 70 2 128 136 38430031
    [Google Scholar]
  47. Jacobs C.T. Kejriwal A. Kocha K.M. Jin K.Y. Huang P. Temporal cell fate determination in the spinal cord is mediated by the duration of Notch signalling. Dev. Biol. 2022 489 1 13 35623404
    [Google Scholar]
  48. Aoyagi-Ikeda K. Maeno T. Matsui H. Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-beta-Smad3 pathway. Am. J. Respir. Cell Mol. Biol. 2011 45 1 136 144 21749980
    [Google Scholar]
  49. Zhou Y. Liao S. Zhang Z. Wang B. Wan L. Astragalus injection attenuates bleomycin-induced pulmonary fibrosis via down-regulating Jagged1/Notch1 in lungs. J. Pharm. Pharmacol. 2016 68 3 389 396 26817817
    [Google Scholar]
  50. Pei C. Wang F. Huang D. Astragaloside IV protects from PM2.5-induced lung injury by regulating autophagy via inhibition of PI3K/Akt/mTOR signaling in vivo and in vitro. J. Inflamm. Res. 2021 14 4707 4721 34557015
    [Google Scholar]
  51. Subramaniam N. Petrik J.J. Vickaryous M.K. VEGF, FGF-2 and TGFβ expression in the normal and regenerating epidermis of geckos: implications for epidermal homeostasis and wound healing in reptiles. J. Anat. 2018 232 5 768 782 29417581
    [Google Scholar]
  52. Liu X. Chen H. Su G. Song P. Jiang M. Gong J. An animal research and a chemical composition analysis of a Chinese prescription for pulmonary fibrosis: Yangfei Huoxue Decoction. J. Ethnopharmacol. 2019 245 112126 31421181
    [Google Scholar]
  53. Jin H. Jiao Y. Guo L. Astragaloside IV blocks monocrotaline-induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling. Int. J. Mol. Med. 2021 47 2 595 606 33416126
    [Google Scholar]
  54. Zhang L. Yang Y. Wang Y. Gao X. Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury. Pharmazie 2011 66 2 144 150 21434579
    [Google Scholar]
  55. Hostettler K.E. Zhong J. Papakonstantinou E. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir. Res. 2014 15 1 157 25496490
    [Google Scholar]
  56. Deng K.M. Yang X.S. Luo Q. She Y.X. Yu Q.Y. Tang X.X. Deleterious role of Th9 cells in pulmonary fibrosis. Cells 2021 10 11 3209 34831433
    [Google Scholar]
  57. Chen S.M. Tsai Y.S. Lee S.W. Astragalus membranaceus modulates Th1/2 immune balance and activates PPARγ in a murine asthma model. Biochem. Cell Biol. 2014 92 5 397 405 25264079
    [Google Scholar]
  58. Liu T. De Los Santos F.G. Phan S.H. The Bleomycin Model of Pulmonary Fibrosis. Methods Mol. Biol. 2017 1627 27 42
    [Google Scholar]
  59. Yu X.Q. Yang S.G. Xie Y. Li J.S. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial. J. Integr. Med. 2020 18 2 163 168 31928920
    [Google Scholar]
  60. Zhang W. Huai Y. Miao Z. Qian A. Wang Y. Systems pharmacology for investigation of the mechanisms of action of traditional chinese medicine in drug discovery. Front. Pharmacol. 2019 10 743 10.3389/fphar.2019.00743
    [Google Scholar]
  61. Panossian A.G. Efferth T. Shikov A.N. Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases. Med. Res. Rev. 2021 41 1 630 703 33103257
    [Google Scholar]
  62. Wang Z. Yip L.Y. Lee J.H.J. Methionine is a metabolic dependency of tumor-initiating cells. Nat. Med. 2019 25 5 825 837 31061538
    [Google Scholar]
  63. Huang H. Peng X. Zhong C. Idiopathic pulmonary fibrosis: The current status of its epidemiology, diagnosis, and treatment in China. Intractable Rare Dis. Res. 2013 2 3 88 93 25343109
    [Google Scholar]
  64. Oravecz M. Mészáros J. Traditional Chinese medicine: theoretical background and its use in China [Traditional Chinese medicine: theoretical background and its use in China Orv. Hetil. 2012 153 19 723 731 22564283
    [Google Scholar]
/content/journals/cmm/10.2174/0115665240396394250911235834
Loading
Astragalus Mongholicus for Idiopathic Pulmonary Fibrosis Treatment: From Molecules to Systems
Bentham Science Publishers ; https://doi.org/10.2174/0115665240396394250911235834
/content/journals/cmm/10.2174/0115665240396394250911235834
/content/journals/cmm/10.2174/0115665240396394250911235834
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: pharmacological mechanism ; idiopathic pulmonary fibrosis treatment ; Traditional Chinese medicine ; systems pharmacology ; Astragalus mongholicus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test